期刊文献+

不同方案新辅助化疗对乳腺癌手术的影响 被引量:2

暂未订购
导出
摘要 目的比较CAF方案和TE方案在乳腺癌新辅助化疗中的效果,为选择更合理的方案提供参考。方法采用随机对照研究方法,对2007年2月-2010年2月在我院收治可手术的乳腺癌患者74例,随机分A、B、C组,A组24例采用CAF方案,B组24例采用TE方案,C组26例在完善术前检查排除手术禁忌症后即行手术治疗,评价三组化疗前后肿块临床触诊情况、超声评价情况及比较三组手术根治率、保乳率和术后切口愈合情况。结果化疗3周期后,A组临床完全缓解、肿块缩小到3em以下分别有4例、11例,B组有4例、12例,2组比较差异无显著性;A组行根治+改良根治术、保乳手术、保乳术后复发率的比例分别为75.0%、37.5%、4.2%,B组为79.2%、41.7%、4.2%,C组为65.4%、19.2%、11.5%,A组与C组、B组与C组比较,差异有显著性,A组与B组比较差异无显著性;3组的切口感染、皮下积液与皮瓣坏死的情况相似。结论CAF方案和TE方案在新辅助化疗效果无明显差异,均具有可缩小原发肿瘤,降低手术难度,缩小手术范围,不增加术后并发症的发生率,提高手术根治率和保乳手术率的作用。
出处 《国际医药卫生导报》 2011年第9期1112-1114,共3页 International Medicine and Health Guidance News
  • 相关文献

参考文献5

二级参考文献25

  • 1吴泰相,刘关键.隐蔽分组(分配隐藏)和盲法的概念、实施与报告[J].中国循证医学杂志,2007,7(3):222-225. 被引量:182
  • 2Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol, 2008, 26:814-819.
  • 3Kaufmann M, Minckwitz GV, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Onco1,2007,18 : 1927-1934.
  • 4Shenoy HG, Peter MB, Masannat YA, et al. Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer. Surg Oncol, 2009,18 ( 1 ) :65-71.
  • 5BamadasA, Gil M, Sanchez-Rovira P, et al. Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anticancer Drugs, 2008, 19:339-347.
  • 6Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol, 2008, 26:778- 785.
  • 7Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. Cancer,2007,110:244-254.
  • 8Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination : the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double -blind randomized trial. J Clin Oncol, 2005,23 : 5108-5116.
  • 9Kaufmann M, Minckwitz GV, Rody A. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast,2005,14:576-581.
  • 10Guarneri V, Frassoldati A, Giovannelli S, et al. Primary systemic therapy for operable breast cancer: a review of chnical trials and perspectives. Cancer Lett,2007,248 : 175-185.

共引文献16

同被引文献15

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部